Amiodarone HCl Injection
"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
Amiodarone HCl Injection
Amiodarone HCl Injection Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Amiodarone HCl Injection is an antiarrhythmic drug used to treat and prevent frequently recurring ventricular fibrillation (VF) and ventricular tachycardia (VT) in patients who don't respond to other therapy. This medication is available in generic form. Common side effects include low blood pressure, asystole/cardiac arrest/electromechanical dissociation (EMD), cardiogenic shock, congestive heart failure, slow heart rate, liver function test abnormalities, VT, and heart block.
The recommended starting dose of intravenous amiodarone is about 1000 mg over the first 24 hours of therapy. Amiodarone HCl may interact with indinavir, cimetidine, graprefruit juice, cyclosporine, simvastatin, digoxin, other antiarrhythmic drugs, beta blockers, calcium channel blockers, warfarin, rifampin, St. John's Wort, fentanyl, lidocaine, dextromethorphan, cholestyramine, disopyramide, antibiotics, azole antifungals, propranolol, diltiazem, and verapamil. Tell your doctor all medications and supplements you use. During pregnancy, amiodarone HCl should be used only if the potential benefit justifies the risk. Amiodarone HCl passes into breast milk. Breastfeeding while using amiodarone HCl is not recommended.
Our Amiodarone HCl Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Amiodarone HCl Injection FDA Prescribing Information: Side Effects
In a total of 1836 patients in controlled and uncontrolled clinical trials, 14% of patients received intravenous amiodarone for at least 1 week, 5% received it for at least 2 weeks, 2% received it for at least 3 weeks, and 1% received it for more than 3 weeks, without an increased incidence of severe adverse reactions. The mean duration of therapy in these studies was 5.6 days; median exposure was 3.7 days.
The most important treatment-emergent adverse effects were hypotension, asystole/cardiac arrest/electromechanical dissociation (EMD), cardiogenic shock, congestive heart failure, bradycardia, liver function test abnormalities, VT, and AV block. Overall, treatment was discontinued for about 9% of the patients because of adverse effects. The most common adverse effects leading to discontinuation of intravenous amiodarone therapy were hypotension (1.6%), asystole/cardiac arrest/EMD (1.2%), VT (1.1%), and cardiogenic shock (1%).
The following table lists the most common (incidence > 2%) treatment-emergent adverse events during intravenous amiodarone therapy considered at least possibly drug-related. These data were collected from the Wyeth-Ayerst clinical trials involving 1836 patients with life-threatening VT/VF. Data from all assigned treatment groups are pooled because none of the adverse events appeared to be dose-related.
SUMMARY TABULATION OF TREATMENT-EMERGENT DRUG-RELATED STUDY
EVENTS IN PATIENTS RECEIVING INTRAVENOUS AMIODARONE IN CONTROLLED AND OPEN-LABEL
STUDIES ( ≥ 2% INCIDENCE)
|Body as a Whole|
|Fever||24 (2.9%)||13 (1.2%)||37 (2.0%)|
|Bradycardia||49 (6.0%)||41 (4.0%)||90 (4.9%)|
|Congestive heart failure||18 (2.2%)||21 (2.0%)||39 (2.1%)|
|Heart arrest||29 (3.5%)||26 (2.5%)||55 (2.9%)|
|Hypotension||165 (20.2%)||123 (12.0%)||288 (15.6%)|
|Ventricular tachycardia||15 (1.8%)||30 (2.9%)||45 (2.4%)|
|Liver function tests abnormal||35 (4.2%)||29 (2.8%)||64 (3.4%)|
|Nausea||29 (3.5%)||43 (4.2%)||72 (3.9%)|
Other treatment-emergent possibly drug-related adverse events reported in less than 2% of patients receiving intravenous amiodarone in controlled and uncontrolled studies included the following: abnormal kidney function, atrial fibrillation, diarrhea, increased ALT, increased AST, lung edema, nodal arrhythmia, prolonged QT interval, respiratory disorder, shock, sinus bradycardia, Stevens-Johnson syndrome, thrombocytopenia, VF, and vomiting.
In postmarketing surveillance, hypotension (sometimes fatal), sinus arrest, pseudotumor cerebri, syndrome of inappropriate antidiuretic hormone secretion (SIADH), toxic epidermal necrolysis (sometimes fatal), exfoliative dermatitis, pancytopenia, neutropenia, erythema multiforme, angioedema, bronchospasm, possibly fatal respiratory disorders (including distress, failure, arrest, and ARDS), fever, dyspnea, cough, hemoptysis, wheezing, hypoxia, pulmonary infiltrates and anaphylactic/anaphylactoid reaction (including shock), hallucination, confusional state, disorientation, and delirium also have been reported with amiodarone therapy.
Also, in patients receiving recommended dosages, there have been postmarketing reports of the following injection site reactions: pain, erythema, edema, pigment changes, venous thrombosis, phlebitis, thrombophlebitis, cellulitis, necrosis, and skin sloughing (see DOSAGE AND ADMINISTRATION).
Read the entire FDA prescribing information for Amiodarone HCl Injection (Amiodarone HCl Injection) »
Additional Amiodarone HCl Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.